Protective Effect of Efonidipine and Amlodipine for Renal Function and Effect for Pretibial Edema (PREFER Study)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002881

Enrollment

246

Registered

2009-12-11

Start date

2009-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

efonidipine40mg efonidipine60mg efonidipine60mg+ARB efonidipine60mg+diuretics efonidipine60mg+ARB+diuretics Amlodipin2.5mg Amlodipin5mg Amlodipin5mg+ARB Amlodipin5mg+diuretics Amlodipin5mg+ARB+diureti

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Newly onset hypertensive patients who are over 15 years old and consent by signature.

Exclusion criteria

Exclusion criteria: Exclusion criteria as follows: Patients who are pregnant or possibility of pregnancy, possess hypersensitivity to efonidipine or amlodipine, who are suffering from secondary hypertension, lateral or bilateral stenosis of renal arteries, cerebro-vascular diseases, hyper-potassemia, severe hepatic diseases, or elevated creatinine over 3.0mg/dl. Patient who are taking NSAID or steroids regularly, who are less than 15 years old, who are suffering from malignant neoplasm. Patients who are not selected by attendant physician. Patient who has pretibial edema at first visit.

Design outcomes

Primary

Measure	Time frame
Incidence of pretibial edema	—

Secondary

Measure	Time frame
Micro-albumin in urine	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026